Are laboratory parameter (biomarker) values similar to the healthy volunteer reference range in all patient populations?

about

Are laboratory parameter (biomarker) values similar to the healthy volunteer reference range in all patient populations?

Item

http://www.wikidata.org/entity/Q58761610

description

im Januar 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Are laboratory parameter (biom ...... ge in all patient populations?

@en

Are laboratory parameter

@nl

type

Item

label

Are laboratory parameter (biom ...... ge in all patient populations?

@en

Are laboratory parameter

@nl

prefLabel

Are laboratory parameter (biom ...... ge in all patient populations?

@en

Are laboratory parameter

@nl

P1476

Are laboratory parameter (biom ...... ge in all patient populations?

@en

P2093

Alexandre Kiazand

http://www.w3.org/2001/XMLSchema#string

David A Brott

http://www.w3.org/2001/XMLSchema#string

Michael J Goodman

http://www.w3.org/2001/XMLSchema#string

Michael Merz

http://www.w3.org/2001/XMLSchema#string

Nadereh Poorkhalkali

http://www.w3.org/2001/XMLSchema#string

Richard P Hermann

http://www.w3.org/2001/XMLSchema#string

Roser Calvo

http://www.w3.org/2001/XMLSchema#string

P2860

Liver safety assessment in special populations (hepatitis B, C, and oncology trials)

Laboratory markers in ulcerative colitis: Current insights and future advances

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony.

Validation of multivariate outlier detection analyses used to identify potential drug-induced liver injury in clinical trial populations.

Clinical correlates of persistently elevated liver enzymes in type 2 diabetic outpatients.

Prevalence and incidence of liver enzyme elevations in a pooled oncology clinical trial cohort.

Nonalcoholic fatty liver (NASH syndrome).

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.

P304

2757-2773

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S173671

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30233139

http://www.w3.org/2001/XMLSchema#string

P921

Farmakologi

drug discovery

biomarker

P932

6132491

http://www.w3.org/2001/XMLSchema#string